Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 11

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

Authors Suzuki S, Hanafusa N, Kubota K, Tsuchiya K, Nitta K

Received 8 March 2018

Accepted for publication 19 May 2018

Published 17 August 2018 Volume 2018:11 Pages 235—240

DOI https://doi.org/10.2147/IJNRD.S167694

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 4

Editor who approved publication: Professor Pravin Singhal


Shunji Suzuki,1,2 Norio Hanafusa,3 Kenji Kubota,1 Ken Tsuchiya,3 Kosaku Nitta2

1Department of Nephrology, Kawaguchi Saiseikai Hospital, Kawaguchi, Japan; 2Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan; 3Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan

Background: Fluid overload in chronic kidney disease (CKD) is generally controlled by diuretics, with potentially harmful effects on renal function. The efficacy of tolvaptan, a vasopressin V2-receptor antagonist and aquaretic, has not been evaluated for fluid control in CKD with reduced renal function.
Methods: Each patient from a group of 24 CKD patients on tolvaptan 15 mg/d plus conventional diuretics (T group) was matched by age and sex with a patient from a group of 24 CKD patients on conventional nonaquaretic diuretics alone not associated to tolvaptan other than tolvaptan (C group). Changes in renal function were compared between the groups for 1 year.
Results: There were no significant differences in blood pressure, hemoglobin levels, cardiac function, urine specific gravity, and urinary sodium concentration between the 2 groups at the beginning of the follow-up period and 1 year after. The estimated glomerular filtration rate (eGFR) by the formula developed by Japanese Society of Nephrology (in mL/min/1.73 m2) decreased: C group (from 28.3±13.6 to 23.0±12.3, p=0.09), T group (from 22.7±12.4 to 19.4±12.2, p=0.18), but both did not reach significance. A 50% reduction in eGFR was observed in 4 patients in the C group and 1 in the T group (p<0.05). A subgroup analysis performed on the patients with stage 3–4 CKD demonstrated a significant reduction in eGFR in the C group (n=17, p=0.04), but not in T group (n=17, p=0.07).
Conclusion: These results suggest that tolvaptan may have less effects on CKD progression among stage 3–4 CKD patients who are on conventional diuretics.

Keywords: tolvaptan, eGFR preservation, observational study, diuretics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]